Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

CELCBullishIndustry Newsnews

High materiality7/10

Celcuity to showcase gedatolisib data across ABC and mCRPC at ESMO 2026

Oct 5, 2026, 8:39 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Conference catalysts often drive short-term price moves for biotech names; positive data or favorable framing at ESMO 2026 could lift CELC sentiment and shares, especially if PIK3CA mutant vs WT analyses show meaningful benefit and potential label expansion.

AI summary

What happened, with direct paths to the underlying reporting

Celcuity announced rapid oral and poster presentations at ESMO 2026 in Madrid, focusing on gedatolisib in HR+/HER2- ABC and mCRPC. Highlights include VIKTORIA-1 updates for PIK3CA mutant and WT cohorts, plus a Phase 1/2 study of gedatolisib with darolutamide. Abstracts publish Oct 19, 2026; data may influence near-term sentiment and label-expansion prospects for CELC.

Celcuity to present VIKTORIA-1 PIK3CA data at ESMO 2026. Posters cover PIK3CA WT and mCRPC analyses.
Rapid oral presentation: VIKTORIA-1 Study 2 updated results vs SOC in HR+/HER2- ABC.
Gedatolisib + darolutamide phase 1/2 poster in metastatic castration-resistant prostate cancer (mCRPC).
VIKTORIA-2 1L HR+/HER2- ABC trial poster planned.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.